Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure

Официальное название

Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure. A Randomized Clinical Trial (KETO-AHF)

Обзор

This is a multicenter, randomized, double-blind, placebo-controlled trial to investigate the clinical efficacy of treatment with exogenous dietary ketone supplement containing 1,3-butanediol in patients hospitalized with acute heart failure (AHF), potentially leading to better clinical outcomes.

Подробное описание

Acute heart failure (AHF) is life-threatening with a 30-day mortality rate between 10% and 50%, especially in patients with cardiogenic shock. Current medical treatments have not shown a survival benefit in randomized trials, highlighting the need for new therapies. Ketone bodies, particularly 3-hydroxybutyrate (3-OHB), are vital for energy in the heart and brain during stress. Elevated 3-OHB levels from exogenous sources, such as ketone esters or 1,3-butanediol, enhance organ perfusion and improve cardiac function. In chronic heart failure (HF), 3-OHB infusion increases cardiac output and left ventricular ejection fraction (LVEF) without excess oxygen consumption, supporting its role as an efficient energy source. Short-term ketone ester treatment has been shown to improve hemodynamics, reduce NT-proBNP, and enhance physical performance in heart failure with reduced ejection fraction (HFrEF) patients. In AHF patients, ketone ester improved cardiac output, LVEF, and filling pressures. Emerging evidence suggests that 1,3-butanediol supplements may sustain ketosis longer, offering potential for practical dosing in the acute phase of heart failure.

This proposal aims to study the clinical efficacy of treatment with exogenous dietary ketone supplement containing 1,3-butanediol in patients hospitalized with AHF.

The primary hypothesis is that in patients hospitalized with AHF, a 30-day treatment with 1,3- butanediol has beneficial clinical effects as compared with placebo. Clinical benefit is defined as a hierarchical composite of death, heart failure (HF) events, change from baseline in the 6-minute walk test (6MWT), and change from baseline in NT-proBNP at 30 days, as assessed using win ratio statistics.

Вмешательства

• Пищевая добавка 1,3-butanediol
  1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
• Пищевая добавка Placebo
  Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily

Первичные конечные точки

• Change in clinical benefit during 1,3-butanediol treatment versus placebo [Срок оценки: From baseline (day 0) to end of treatment (day 30)]

Вторичные конечные точки (12)

• Time to all-cause death [Срок оценки: From baseline (day 0) to end of treatment (day 30)]
• Time to first heart failure event [Срок оценки: From baseline (day 0) to end of treatment (day 30)]
• Change in six-minute walking distance [Срок оценки: From baseline (day 0) to end of treatment (day 30)]
• Change in daily activity level [Срок оценки: From discharge, day 30, and end of treatment (day 30)]
• Change in NT-proBNP [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Change in KCCQ-12 total summary score [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Change in VAS dyspnea score [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Change in physical exertion score during six- minute walk test [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Change in systolic blood pressure [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Change in body weight [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Diuretic response [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]
• Cumulative dose of loop diuretic medication [Срок оценки: From baseline (day 0) to discharge and end of treatment (day 30)]

Критерии участия

The study will enroll adult patients (≥18 years) admitted with AHF as the primary diagnosis, meeting all the following criteria:

• Documented new or worsening symptoms due to heart failure with at least one of the following: persistent dyspnea at rest or with minimal exertion, or fatigue.
• Objective evidence of worsening heart failure, consisting of at least two physical examination findings consistent with fluid retention and/or end-organ hypoperfusion or one physical examination finding and at least one laboratory criterion:

a) Physical examination findings considered to be due to heart failure, including new or worsened: i. Peripheral edema ii. Increasing abdominal distention or ascites (in the absence of primary hepatic disease) iii. Pulmonary rales/crackles/crepitations iv. Increased jugular venous pressure and/or hepatojugular reflux v. S3 gallop vi. Clinically significant or rapid weight gain thought to be related to fluid retention b) Laboratory evidence of worsening HF, if obtained within 24 hours of presentation, including: i. Increased B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure. In patients with chronically elevated natriuretic peptides, an increase of \>30% above baseline should be noted.

ii. Radiological evidence of pulmonary congestion iii. Echocardiographic criteria include: Dilated inferior vena cava with minimal collapse on inspiration; decreased left ventricular outflow tract (LVOT) minute stroke distance (velocity time integral \[VTI\]); septal or lateral E/e' \>15 or \>12, respectively; D-dominant pulmonary venous inflow pattern.

iv. Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure ≥18 mmHg, central venous pressure ≥12 mmHg, or a cardiac index \<2.2 L/min/m2

• Treatment with at least 40 mg of intravenous furosemide or its equivalent and/or intravenous vasoactive drugs and/or inotropic drugs.
• An LVEF of ≤35% is required, measured during the present hospitalization.
• Participants must present with elevated levels of natriuretic peptides, specifically NT-proBNP ≥600 pg/mL or BNP ≥150 pg/mL. For those in atrial fibrillation at the time of inclusion, NT-proBNP levels must be ≥900 pg/mL or BNP ≥225 pg/mL.

The enrollment window extends to the first five days of the hospital stay.

Критерии исключения

• Current hospitalization for AHF triggered by significant arrhythmia (atrial fibrillation/flutter with sustained ventricular response \>110 beats per minute, clinically significant bradycardia, or sustained ventricular tachycardia)
• Cardiogenic shock in INTERMACS level 1 or 2 (i.e. unstable hemodynamics despite inotropic/vasopressor therapy)
• Likelihood or current use of mechanical circulatory support
• Recent cardiac surgery within 3 days
• Ongoing severe infection or sepsis, severe anemia, acute exacerbation of chronic obstructive pulmonary disease, pulmonary embolism, or cerebrovascular accident
• Significant primary valvular disease (hemodynamically severe uncorrected primary cardiac valvular disease)
• Planned implantation of a cardiac resynchronization therapy device
• eGFR \<15 mL/min/1.73 m2 during current hospitalization (unless ongoing continuous renal replacement therapy) or recurring dialysis
• Known obstructive hypertrophic cardiomyopathy, congenital heart disease, acute mechanical cause of acute heart failure (e.g., papillary muscular rupture), acute myocarditis, or constrictive pericarditis according to the treating physician
• Type 1 diabetes
• Advanced liver disease (Child-Pugh class C)
• Dementia or other cognitive disorder making the patient unable to give informed consent
• Pregnancy or breastfeeding
• Inability to intake oral substances or severe dysphagia
• Significant gastrointestinal disease (i.e. severe inflammatory bowel disease or gastric ulcer)
• Adherent to a ketogenic diet within 30 days of enrollment
• Awaiting cardiac transplantation
• Very severe lung disease and/or treatment with continuous home oxygen therapy
• Major comorbidity, medical condition, or health issue that, according to the investigator's judgment, would hinder the participant's capacity to engage in or successfully finish the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Дания · 8 центров

• Department of Cardiology, Aalborg University Hospital — Aalborg
• Department of Cardiology, Aarhus University Hospital — Aarhus N
• Department of Cardiology, Herlev-Gentofte Hospital — Copenhagen
• Department of Cardiology, Rigshospitalet — Copenhagen
• Department of Cardiology, Gødstrup Hospital, Herning, Denmark — Herning
• Department of Cardiology, Copenhagen University Hospital - Amager and Hvidovre Hospital — Hvidovre
• Department of Cardiology, Odense University Hospital — Odense
• Department of Cardiology, Viborg Hospital — Viborg

Публикации

• Kodur N, Nguyen C, Tang WHW. Therapeutic Ketosis for Heart Failure: A State-of-the-Art Review. J Card Fail. 2025 Jul;31(7):1051-1061. doi: 10.1016/j.cardfail.2025.01.028. Epub 2025 Mar 3. PMID 40043832

Идентификаторы

NCT: NCT06653725 · KETO-AHF · 1-10-72-63-24

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗